Annual report pursuant to Section 13 and 15(d)

Agreements (Details)

v2.4.0.6
Agreements (Details) (USD $)
12 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 84 Months Ended 12 Months Ended 0 Months Ended 12 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2010
Jul. 31, 2012
Dec. 31, 2012
Supply Agreement [Member]
Dec. 31, 2011
Supply Agreement [Member]
Dec. 31, 2010
Supply Agreement [Member]
Apr. 30, 2008
Research And Development Agreement [Member]
Jan. 31, 2002
Research And Development Agreement [Member]
Apr. 30, 2008
Research And Development Agreement [Member]
Minimum [Member]
Jan. 31, 2002
Research And Development Agreement [Member]
Minimum [Member]
Dec. 31, 2012
Employment Agreement [Member]
Minimum [Member]
Dec. 31, 2012
Employment Agreement [Member]
Maximum [Member]
Dec. 31, 2012
Astra Zeneca Agreement [Member]
Dec. 31, 2011
Astra Zeneca Agreement [Member]
Milestone Payments Based On Achievement Of Certain Clinical Development And Regulatory Filing Milestones [Member]
Dec. 31, 2011
Astra Zeneca Agreement [Member]
Milestone Payments Based On Achievement Of Certain Clinical Development And Regulatory Filing Milestones [Member]
Dec. 31, 2011
Astra Zeneca Agreement [Member]
Maximum [Member]
Milestone Payments Based On Receipt Of Certain Regulatory Approvals And Initiation Of Commercial Sales Of Licensed Product [Member]
Jul. 31, 2012
Alseres Pharmaceuticals Inc [Member]
Dec. 31, 2012
Alseres Pharmaceuticals Inc [Member]
Jul. 31, 2012
Alseres Pharmaceuticals Inc [Member]
Alseres Milestone Payments Based On Product Registration Or Commercial Sales [Member]
Jul. 31, 2012
Alseres Pharmaceuticals Inc [Member]
Milestone Payments Maximum [Member]
Dec. 31, 2012
Cardiosonix [Member]
Dec. 31, 2012
Cardiosonix [Member]
Minimum [Member]
Dec. 31, 2012
Cardiosonix [Member]
Maximum [Member]
Dec. 31, 2012
Lymphoseek License Agreement [Member]
Dec. 31, 2011
Lymphoseek License Agreement [Member]
Dec. 31, 2010
Lymphoseek License Agreement [Member]
Dec. 31, 2012
Lymphoseek Expanded License Agreement [Member]
Dec. 31, 2011
Lymphoseek Expanded License Agreement [Member]
Dec. 31, 2010
Lymphoseek Expanded License Agreement [Member]
Jan. 31, 2006
Cira License Agreement [Member]
Dec. 31, 2012
Cira License Agreement [Member]
Agreements [Line Items]                                                                
Purchases under manufacture and supply agreement         $ 939,000 $ 544,000 $ 1,000,000                                                  
Purchase orders issued         119,000                                                      
License fee               25,000 25,000           5,000,000                               5,000  
License maintenance fee               25,000 25,000                                              
Royalty on net sales of licensed products , percentage               5.00% 5.00%                           3.00% 5.00%                
Research and development 16,890,482 15,154,365 8,941,046                     14,000   5,000,000     1,800,000           33,000 98,000 36,000 31,000 28,000 27,000 100,000 100,000
Common stock, shares issued 113,018,772 95,398,961                               300,000   950,000 1,150,000                      
Contingent milestone payment       2,900,000                     6,500,000 6,500,000 11,000,000     2,500,000 2,900,000                      
Royalty percentage on grant revenues                                               300.00%                
Royalty expense 100,000                 25,000 25,000                     82,000                 100,000  
Percentage of sublicense fees (royalties)               50.00% 50.00%                                              
Accrued royalties                                           1,000                    
Maximum contingent liability                         3,100,000                                      
Ratio of entitled salary                       1.5 2.5                                      
Sublicense execution payment, cash paid                                   175,000                            
Grants received from Office of the Chief Scientist                                           $ 775,000